Private Capital Advisors Inc. Trims Stake in Eli Lilly and Company $LLY

Private Capital Advisors Inc. reduced its stake in Eli Lilly and Company (NYSE:LLY) by 0.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 433,322 shares of the company’s stock after selling 458 shares during the period. Eli Lilly and Company accounts for approximately 41.1% of Private Capital Advisors Inc.’s holdings, making the stock its largest holding. Private Capital Advisors Inc.’s holdings in Eli Lilly and Company were worth $337,787,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. D.A. Davidson & CO. boosted its position in shares of Eli Lilly and Company by 5.0% in the 2nd quarter. D.A. Davidson & CO. now owns 46,111 shares of the company’s stock worth $35,945,000 after purchasing an additional 2,211 shares during the last quarter. Blume Capital Management Inc. raised its stake in Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the period. Gables Capital Management Inc. raised its stake in Eli Lilly and Company by 10.6% during the 2nd quarter. Gables Capital Management Inc. now owns 2,899 shares of the company’s stock worth $2,260,000 after buying an additional 278 shares during the period. Cullen Frost Bankers Inc. raised its stake in Eli Lilly and Company by 1.0% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 103,839 shares of the company’s stock worth $80,946,000 after buying an additional 1,075 shares during the period. Finally, Smith Thornton Advisors LLC raised its stake in Eli Lilly and Company by 8.4% during the 2nd quarter. Smith Thornton Advisors LLC now owns 901 shares of the company’s stock worth $703,000 after buying an additional 70 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Skovronsky acquired 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 over the last three months. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $799.85 on Wednesday. The stock has a market capitalization of $757.03 billion, a price-to-earnings ratio of 52.28, a PEG ratio of 1.16 and a beta of 0.47. The business has a 50-day moving average of $759.77 and a 200-day moving average of $766.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. BMO Capital Markets lifted their price target on Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a research note on Monday. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a research note on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.